<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="93">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 22, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00899769</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000546781</org_study_id>
    <secondary_id>VU-VICC-HN-0530</secondary_id>
    <secondary_id>VU-VICC-IRB-050230</secondary_id>
    <nct_id>NCT00899769</nct_id>
  </id_info>
  <brief_title>Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers</brief_title>
  <official_title>Serum Biomarkers for Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>Unspecified</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood, tissue, and saliva in the laboratory from patients
      with cancer and from healthy volunteers may help doctors identify and learn more about
      biomarkers related to cancer.

      PURPOSE: This laboratory study is looking at biomarkers in patients with head and neck
      cancer and in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Correlate the differences in serum protein profiles with the differences in the number
           of peptide matches in patients with squamous cell carcinoma of the head and neck and in
           healthy volunteers.

        -  Correlate protein levels with the largest difference in peptide matches in sera in
           these participants.

      OUTLINE: This is a prospective study.

      Participants undergo blood, tissue, and saliva collection for biological studies. Samples
      are analyzed for albumin-bound and non-albumin-bound proteins or IgG via liquid
      chromatography and tandem mass spectrometry (LC-MS-MS), ELISA, proteomic profiling, and
      protein expression.

      PROJECTED ACCRUAL: A total of 50 patients and 50 healthy volunteers will be accrued for this
      study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2005</start_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>Differences in serum protein profiles and differences in the number of peptide matches</measure>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Protein levels and the largest difference in peptide matches in sera</measure>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>proteomic profiling</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>liquid chromatography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mass spectrometry</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Meets one of the following criteria:

               -  Diagnosis of squamous cell carcinoma of the head and neck

               -  Healthy volunteer matched by sex, race, birth decade, or smoking status (e.g.,
                  current smoker, former smoker, or nonsmoker)

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendell G. Yarbrough, MD, FACS</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center - Cool Springs</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendell G Yarbrough</last_name>
      <phone>615-343-8840</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center at Franklin</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendell G Yarbrough</last_name>
      <phone>615-343-8840</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Vanderbilt-Ingram Cancer Center</last_name>
      <phone>800-811-8480</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <lastchanged_date>August 11, 2009</lastchanged_date>
  <firstreceived_date>May 9, 2009</firstreceived_date>
  <keyword>metastatic squamous neck cancer with occult primary squamous cell carcinoma</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage I squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the larynx</keyword>
  <keyword>stage I squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage I squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the larynx</keyword>
  <keyword>stage II squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>untreated metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>salivary gland squamous cell carcinoma</keyword>
  <keyword>stage I salivary gland cancer</keyword>
  <keyword>stage II salivary gland cancer</keyword>
  <keyword>stage III salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
